What Is the Partnership?
Dr. Reddy's Laboratories has entered into a strategic collaboration with Takeda Biopharmaceuticals India to manage the exclusive distribution and marketing of the Qdenga vaccine in India's private healthcare sector. Takeda will maintain legal ownership, brand oversight, and the rights to distribute the vaccine in the public market.
Additionally, Takeda remains responsible for the manufacturing and importation of the vaccine. While specific commercial terms are confidential, the filing confirms there are no upfront or milestone payments involved. The partnership combines Takeda's vaccine expertise with Dr.
Reddy's distribution network to address the growing dengue burden in India.
Partner Profile
- Takeda is a Japan-based global biopharmaceutical leader with over 245 years of history and operations in 80 countries
- Qdenga (TAK-003) is a live-attenuated tetravalent vaccine approved in 43 countries including Indonesia, Thailand, and Brazil
- Over 32 million doses of the vaccine have been distributed globally through public and private programs since 2022
- The vaccine has been listed in the World Health Organization's List of Prequalified Vaccines since May 2024
- Clinical trials involving 60,000 participants demonstrated sustained efficacy across all four virus serotypes over seven years
What It Unlocks
This agreement provides a critical pathway for private-market access to the first dengue vaccine authorized by the Central Drugs Standard Control Organization. India has faced an 11-fold increase in dengue cases over the last two decades, with all four virus serotypes co-circulating. Recent surveillance data shows that approximately 1 in 14 patients are infected with multiple serotypes concurrently.
By securing exclusive private-market rights, Dr. Reddy's strengthens its vaccine portfolio and aligns with national health efforts to mitigate a year-round epidemic. The vaccine is administered in a two-dose regimen, three months apart, for individuals aged 4 to 60 years.
Financial Context
- Dr. Reddy's reports an annual operating revenue of 33,700.2 crore with a TTM net profit of 3,222.2 crore
- The company's stock trades at a TTM P/E of 29.66, significantly lower than the industry average P/E of 48.21
- Promoter holding remains stable at 26.64 percent, while institutional investors hold a majority 63.83 percent stake
- The firm maintains a mid-range performance profile with a Trendlyne Durability Score of 55 and a Piotroski Score of 5
- Total assets generate a return on assets of 7.21 percent, compared to the sector average of 10.42 percent
Strategic Rationale
As the second-largest vaccine player in India, we believe the introduction of India’s first approved dengue vaccine is an important development for the country’s healthcare landscape. Through our collaboration with Takeda, we look forward to making QDENGA available to eligible individuals and contributing to efforts aimed at addressing the country’s dengue burden.
